Protocol Ledger

NCT07096778 · Phase II · RECRUITING

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Interventional Phase II clinical trial protocol NCT07096778 sponsored by CellCentric in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-22 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07096778
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07096778
Protocol FieldVerified Registry Value
NCT IdentifierNCT07096778
Consolidated Lead SponsorCellCentric
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2026-01-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07096778
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
Mayo Clinic FloridaJacksonville, FLOpen Hospital Dossier ->
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI